ETROLIZUMAB Anti-alpha E beta 7/alpha 4 beta 7 monoclonal antibody Prop INN; USAN Treatment of inflammatory bowel disease

摘要

Etrolizumab is a humanized IgG(1) monoclonal antibody (MAb) targeting the beta 7 subunit of integrins alpha 4 beta 7 and alpha E beta 7. It is being developed as potential new treatment of the two main forms of inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD). The safety of etrolizumab was demonstrated in phase I trials, advancing the drug to phase II studies in patients with UC. Randomized phase II trials evaluated two doses of subcutaneous etrolizumab in patients with moderate to severely active UC, showing significantly improved clinical remission at 10 weeks compared the placebo. The apparent safety and efficacy of etrolizumab in phase II studies warranted further development of the drug candidate, which is currently being studied in a number of phase III trials evaluating the drug in patients with UC and CD.